LYEL
Lyell Immunopharma Inc
NASDAQ: LYEL · HEALTHCARE · BIOTECHNOLOGY
$19.73
-4.22% today
Updated 2026-04-30
Market cap
$527.78M
P/E ratio
—
P/S ratio
14,660.60x
EPS (TTM)
$-16.06
Dividend yield
—
52W range
$8 – $45
Volume
0.1M
Lyell Immunopharma Inc (LYEL) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $39.47M | $-160.87M | $-126.25M | $-169.56M | $-163.69M | $-162.39M | $-150.02M |
| Capital expenditures | $16.05M | $51.48M | $65.50M | $24.28M | $2.69M | $464000.00 | $780000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $15.73M | $33.26M | $62.20M | $81.92M | $47.08M | $33.14M | $41.83M |
| Free cash flow | $23.43M | $-212.35M | $-191.75M | $-193.83M | $-166.38M | $-162.86M | $-150.80M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $153.42M | — | — | — | — |